Advertisement
Advertisement
U.S. markets open in 4 hours 10 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Edoc Acquisition Corp. (ADOCR)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.1200+0.0200 (+20.00%)
At close: 12:54PM EST
0.1200 -0.00 (-0.00%)
Pre-Market: 04:06AM EST
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    EDOC Acquisition Corp. Announces Business Combination Agreement with Australian Oilseeds Investments Pty Ltd.,

    ~ Over the past 20 years, the Company has grown the business to be the largest cold pressing oil plant in Australia, pressing strictly GMO free conventional and organic oilseeds ~ ~ Combined company expected to have a post-transaction enterprise value of approximately $190 million ~ ~ The global oilseeds market is estimated at $264.87 billion in 2022 ~ ~ The oilseeds market is expected to grow to $340.44 billion in 2026 at a compound annual growth rate (CAGR) of 5.7% ~ Victor, NY, Dec. 07, 2022

  • GlobeNewswire

    EDOC Acquisition Corp. Announces Voting Results of Extraordinary General Meeting to Approve the Extension Amendment

    New York, NY, Aug. 15, 2022 (GLOBE NEWSWIRE) -- EDOC Acquisition Corp. (Nasdaq: ADOC, ADOCR, ADOCW, “EDOC” or the “Company”), a special purpose acquisition company, announced today that the Company’s shareholders voted in favor of the proposal to amend its charter (the “Extension Amendment”) to extend the date by which the Company has to complete a business combination from August 12, 2022 to February 12, 2023 (the “Extension”), at the extraordinary general meeting of EDOC shareholders that took

  • GlobeNewswire

    Edoc Acquisition Corp. Announces Termination of Merger Agreement with Calidi Biotherapeutics, Inc.

    New York, NY, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Edoc Acquisition Corp. (Nasdaq: ADOC, ADOCR, ADOCW, “EDOC” or the “Company”), a special purpose acquisition company, announced today the termination of its previously announced agreement and plan of merger (the “Merger Agreement”) with Calidi Biotherapeutics, Inc. (“Calidi”). Although Edoc and Calidi may continue to discuss the possibility of engaging in a business combination, there can be no assurance that those discussions will result in a trans

Advertisement
Advertisement